Characterization of gene expression induced by RET with MEN2A or MEN2B mutation

American Journal of Pathology

Volumn 161, Issue 1, 2002, Pages 249-256

  Watanabe, Tsuyoshi ^a   Ichihara, Masatoshi ^a   Hashimoto, Mizuo ^a   Shimono, Keiko ^a   Shimoyama, Yoshie ^a   Nagasaka, Tetsuro ^a   Murakumo, Yoshiki ^a   Murakami, Hideki ^a   Sugiura, Hideshi ^a   Iwata, Hisashi ^a   Ishiguro, Naoki ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; CATHEPSIN B; CATHEPSIN L; COFILIN; COLLAGEN TYPE 1; CYCLIN D1; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HYPOCALCIN; LIPOCORTIN 1; PROTEIN LYSINE 6 OXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL GROWTH; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROBLASTOMA CELL; NEUROFIBROMATOSIS; NONHUMAN; ONCOGENE RET; PHEOCHROMOCYTOMA; POINT MUTATION; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

EID: 0036314247     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64176-4     Document Type: Article

References (59)

1. The GDNF/RET signaling pathway and human diseases
2. The RET receptor: Function in development and dysfunction in congenital malformation
3. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
4. Renal and neuronal abnormalities in mice lacking GDNF
5. Defects in enteric innervation and kidney development in mice lacking GDNF
6. Renal agenesis and the absence of enteric neurons in mice lacking GDNF
7. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
8. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
9. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
10. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B
11. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations
12. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
13. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation
14. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway
15. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor
16. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase
17. Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation
18. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins
19. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma
20. Possible roles for stanniocalcin during early skeletal patterning and joint formation in the mouse
21. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation
22. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck
23. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling
24. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B
25. Increased expression of cyclin D1, cyclin E and p21(Cip1) associated with decreased expression of p27(Kip1) in chemically induced rat mammary carcinogenesis
26. Cysteine proteinases in cancer progression and their clinical relevance for prognosis
27. Cathepsin B and human tumor progression
28. Live dynamics of Dictyostelium cofilin suggests a role in remodeling actin latticework into bundles
29. Proteogrycans of the extracellular matrix and growth control
30. Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells
31. Cloning and expression profile of mouse and human genes, Rnf11/RNF11, encoding a novel RING-H2 finger protein
32. Yop1p, the yeast homolog of the polyposis locus protein 1, interacts with Yip1p and negatively regulates cell growth
33. Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors
34. Lysyl oxidases: A novel multifunctional amine oxidase family
35. Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer
36. Immune system dysfunction and autoimmune disease in mice lacking Emk (Par-1) protein kinase
37. Defective learning in mutants of the Drosophila gene for a regulatory subunit of cAMP-dependent protein kinase
38. Alpha 6 beta 4 integrin abnormalities in junctional epidermolysis bullosa with pyloric atresia
39. Essential role of alpha 6 integrins in cortical and retinal lamination
40. The TACC domain identifies a family of centrosomal proteins that can interact with microtubules
41. Expression of neuropsin in oligodendrocytes after injury to the CNS
42. Phosphorylation of eukaryotic initiation factor 4E (elF4E) at Ser209 is not required for protein synthesis in vitro and in vivo
43. Studies on the regulation and characterization of plasma stanniocalcin in rainbow trout
44. A novel human cDNA highly homologous to the fish hormone stanniocalcin
45. Stanniocalcin: A novel protein regulating calcium and phosphate transport across mammalian intestine
46. The distribution of stanniocalcin 1 protein in fetal mouse tissues suggests a role in bone and muscle development
47. Effects of a synthetic N-terminal fragment of stanniocalcin on the metabolism of mammalian bone in vitro
48. Evidence for stanniocalcin gene expression in mammalian bone
49. Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells
50. cAMP signaling can antagonize potent glucocorticoids post-transcriptional inhibition of stanniocalcin gene expression
51. Expression of stanniocalcin in zona glomerulosa and medulla of normal human adrenal glands, and some adrenal tumors and cell lines
52. Transcriptional response to hypoxia in human tumors
53. Assessment of stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers
54. High expression of stanniocalcin in differentiated brain neurons
55. Stanniocalcin: A molecular guard of neurons during cerebral ischemia
56. Glial cell line-derived neurotrophic factor protects against ischemia-induced injury in the cerebral cortex
57. Stanniocalcin gene expression during mouse urogenital development: A possible role in mesenchymal-epithelial signalling
58. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF
59. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues